biostudies-literatureKeating NLCenters for Medicare &amp; Medicaid Services (CMS) to evaluate the CMS Oncology Care Model871-877https://www.ebi.ac.uk/biostudies/studies/S-EPMC9194623biostudies-literatureUnknown114(6)<h4>Background</h4>Adherence to oral cancer drugs is suboptimal. The Oncology Care Model (OCM) offers oncology practices financial incentives to improve the value of cancer care. We assessed the impact of OCM on adherence to oral cancer therapy for chronic myelogenous leukemia (CML), prostate cancer, and breast cancer.<h4>Methods</h4>Using 2014-2019 Medicare data, we studied chemotherapy episodes for Medicare fee-for-service beneficiaries prescribed tyrosine kinase inhibitors (TKIs) for CML, antiandrogens (ie, enzalutamide, abiraterone) for prostate cancer, or hormonal therapies for breast cancer in OCM-participating and propensity-matched comparison practices. We measured adherence as the proportion of days covered and used difference-in-difference (DID) models to detect changes in adhereJournal of the National Cancer InstituteThe Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.PMC9194623HHSM-500-2014-00026IWolf RLandrum MBJhatakia SHassol ABrooks GAHsu VDLiu PHKummet CMKeating NLKapadia NSTripp ARiedel LESimon CfalseThe Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.<h4>Background</h4>Adherence to oral cancer drugs is suboptimal. The Oncology Care Model (OCM) offers oncology practices financial incentives to improve the value of cancer care. We assessed the impact of OCM on adherence to oral cancer therapy for chronic myelogenous leukemia (CML), prostate cancer, and breast cancer.<h4>Methods</h4>Using 2014-2019 Medicare data, we studied chemotherapy episodes for Medicare fee-for-service beneficiaries prescribed tyrosine kinase inhibitors (TKIs) for CML, antiandrogens (ie, enzalutamide, abiraterone) for prostate cancer, or hormonal therapies for breast cancer in OCM-participating and propensity-matched comparison practices. We measured adherence as the proportion of days covered and used difference-in-difference (DID) models to detect changes in adhere2022-01-01T00:00:00Z2022 Jun2026-07-16T20:12:19.709Z2025-04-06T02:21:09.102ZS-EPMC91946233513497210.1093/jnci/djac026